Medicortex Finland is dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Current focus is on the development of biomarker diagnostics to evaluate the extent and severity of concussion and traumatic brain injury. Once the development of the diagnostic kit is more advanced, the next goal is to expand the program to the development of an innovative drug to halt the aggravation of brain injury.
Medicortex Finland Oyj was founded in June 2014 as a BioTurku member; it is located in Werstas bioincubator in the heart of Turku Science Park. The company has received funding from Business Finland, twice from United States Department of Defense, Horizon-2020 innovation grant and the Finnish ELY-center (The Centre for Economic Development, Transport and the Environment), as well as from private investors.
Our nearest aim is to develop a handheld quick diagnostic kit for detection of concussions. The kit is based on the proprietary biomarker we have studied in several clinical trials.